Successful nilotinib treatment in a patient with chronic myelogenous leukemia after failure of treatment with two tyrosine kinase inhibitors due to intolerance and resistance

Abstract

Treatment with tyrosine kinase inhibitors (TKI) produces good results in patients with chronic
myelogenous leukemia (CML). However, some patients need to change the therapy due to intolerance
or resistance to TKI applied. In these situations, the possibility of 2nd generation TKI administration
allows to achieve deep molecular response (DMR) and long survival of patients. In this
paper, a case of adult patient with CML who experienced hepatic toxicity of imatinib and failure
of dasatinib treatment due to resistance is presented. Subsequently, the treatment with nilotinib
resulted in a long-term DMR.